



US005906974A

# United States Patent [19]

[11] **Patent Number:** **5,906,974**

**Blue et al.**

[45] **Date of Patent:** **\*May 25, 1999**

[54] **HEMOGLOBIN THERAPY IN HEMODIALYSIS**

[75] Inventors: **John Blue**, Gurnee; **Jan W. Garber**, Barrington; **Janet C. Gonder**; **Gary R. Marchand**, both of Crystal Lake, all of Ill.; **Robert J. Przybelski**, Fitchburg, Wis.; **Kathleen N. Stern**, Lake Zurich, Ill.

5,296,466 3/1994 Kilbourn ..... 514/6  
 5,439,882 8/1995 Feola et al. .  
 5,480,866 1/1996 Bonaventura et al. .... 514/6

[73] Assignee: **Baxter International, Inc.**, Deerfield, Ill.

### FOREIGN PATENT DOCUMENTS

657212 9/1993 Australia .  
 2087504 7/1993 Canada .  
 9013309 11/1990 WIPO .  
 9316721 2/1993 WIPO .  
 9524213 9/1995 WIPO .

[\*] Notice: This patent issued on a continued prosecution application filed under 37 CFR 1.53(d), and is subject to the twenty year patent term provisions of 35 U.S.C. 154(a)(2).

### OTHER PUBLICATIONS

Medline Abstract AN 902 21208, Bergonzi et al, 1990.  
 Amerling et al. Complications During Hemodialysis Clinical Dialysis, Alpelton & Lang, 3rd Edition, pp. 235-267.  
 Bradley et al. Is Dialysis Hypotension Caused by an Abnormality of Venous Tone? Br. Med. J. (Clin. Res. Ed.), vol. 296, pp. 1634-1637, (abstract), 1988.  
 Kouw et al. Interstitial Correction of Blood Volume Decrease During Hemodialysis Int. J. Artif. Organs vol. 12, No. 10, pp. 626-631, (abstract), 1989.  
 Levin et al. Complications During Hemodialysis Clinical Dialysis, pp. 172-197.

[21] Appl. No.: **08/701,812**

[22] Filed: **Aug. 21, 1996**

(List continued on next page.)

### Related U.S. Application Data

[63] Continuation of application No. 08/340,987, Nov. 17, 1994, abandoned, which is a continuation-in-part of application No. 08/330,277, Oct. 27, 1994, abandoned.

[51] **Int. Cl.<sup>6</sup>** ..... **A61K 38/16**; A61K 39/395; A61K 35/14

[52] **U.S. Cl.** ..... **514/6**; 424/177; 424/101; 530/385

[58] **Field of Search** ..... 514/6; 424/177, 424/101; 530/385

*Primary Examiner*—Keith D. MacMillan  
*Attorney, Agent, or Firm*—Senniger, Powers, Leavitt & Roedel

### [57] ABSTRACT

Low doses of stroma-free diaspirin cross-linked hemoglobin are administered to patients undergoing hemodialysis, to achieve hemostabilization and avoid hypotensive episodes in susceptible patients. Hemoglobin therapy when implemented prophylactically in hemodialysis also partially obviates the need for further interventions to control circulatory system instability.

### [56] References Cited

#### U.S. PATENT DOCUMENTS

4,001,401 1/1977 Bonsen et al. .... 514/6  
 4,757,052 7/1988 Markov ..... 514/23

**26 Claims, 3 Drawing Sheets**